Threshold Pharmactl (THLD) 0.47 $THLD
Threshold Pharmaceuticals Highlights Multiple Presentations at the 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 7:30AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced multiple presentations on clinical trials on its hypoxia-activated prodrugs, evofosfamide and tarloxotinib at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 through 7, 2016 in Chicago, Ill.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 7:30AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Jefferies 2016 Healthcare Conference at the Grand Hyatt in New York City on June 7, 2016 at 3:30 p.m. Eastern Time.
THLD: 0.47 (-0.02)
What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech
PR Newswire - Wed May 18, 7:38AM CDT
The Biotech industry continues to face a wave of challenges, but it does not mean that there are no opportunities ahead. Today, ActiveWallSt.com has on its list these four equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Seattle Genetics Inc. (NASDAQ: SGEN), Chiasma Inc. (NASDAQ: CHMA), and Ophthotech Corp. (NASDAQ: OPHT). Sign up now to receive our free insights and trading alerts at:
SGEN: 40.38 (-0.63), OPHT: 56.33 (+0.17), THLD: 0.47 (-0.02), CHMA: 2.91 (-0.23)
Threshold Pharmaceuticals posts 1Q loss
Automated Insights - Thu May 05, 5:28PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Threshold Pharmaceuticals Inc. (THLD) on Thursday reported a loss of $7.9 million in its first quarter.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Appoints Stew Kroll as Chief Operating Officer
GlobeNewswire - Mon Mar 21, 7:00AM CDT
Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, announced the appointment of Stewart M. Kroll as Chief Operating Officer. Mr. Kroll will serve as the Company's principal operating officer, will continue to report to Barry Selick, CEO, and will be responsible for the design and execution of Threshold's clinical development programs.
THLD: 0.47 (-0.02)
Top Penny Stocks to Watch, Friday 3/11/2016
ACCESSWIRE - Fri Mar 11, 9:56AM CST
CORAL GABLES, FL / ACCESSWIRE / March 11, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. THLD, VCEL, KTOS, and PPCH have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, NASDAQ, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals posts 4Q profit
Automated Insights - Thu Mar 10, 6:29PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Threshold Pharmaceuticals Inc. (THLD) on Thursday reported fourth-quarter net income of $69.7 million, after reporting a loss in the same period a year earlier.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Thu Mar 10, 3:05PM CST
-- Rights to Evofosfamide and Relevant Merck KGaA, Darmstadt, Germany Technology Returned to Threshold; Merck KGaA, Darmstadt, Germany Retains Certain Royalty and Milestone Payments Dependent Upon Successful Development and Commercialization of Evofosfamide --
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Announces Workforce Reduction
Marketwired - Fri Dec 18, 3:05PM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it has initiated a significant reduction in its workforce in order to focus the company's financial resources in the near term on two ongoing Phase 2 proof-of-concept clinical trials of tarloxotinib bromide* ("tarloxotinib"
, the company's novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) licensed from the University of Auckland, New Zealand.
THLD: 0.47 (-0.02)
The Only Bit of "Good News" From 2015
ACCESSWIRE - Mon Dec 14, 10:08AM CST
WINDSOR, ON / ACCESSWIRE / December 14, 2015 / The Wealthy Biotech Trader (or "WBT", an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device and general healthcare stocks making news and subsequent market moves, would like to mention a few highlights from 2014/ 2015 in the crazy world of biotech investing.
IMMU: 3.05 (-0.08), ADRO: 11.99 (-0.43), MRK: 56.81 (-0.37), AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48), THLD: 0.47 (-0.02), BMY: 72.65 (-0.08)
Beyond Chemotherapy: 4 Unique Ways Drug Developers Are Fighting Back Against Cancer
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 22, 8:12AM CST
Image source: National Cancer Institute. Cancer drugs are a fast-growing business for drug developers. According to figures from IMS Health , global oncology sales topped $100 billion in 2014, and this figure could grow by as much as 47% by 2018....
OMED: 11.81 (-0.04), PFE: 35.29 (-0.02), MRK: 56.81 (-0.37), THLD: 0.47 (-0.02), BMY: 72.65 (-0.08)
Threshold Pharmaceuticals Enters Into Definitive Co-Promotion Agreement for Evofosfamide With Merck KGaA, Darmstadt, Germany
Marketwired - Wed Nov 18, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck KGaA, Darmstadt, Germany pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide (previously known as TH-302) in the U.S. subject to Food and Drug Administration (FDA) approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2015 Healthcare Conference
Marketwired - Wed Nov 11, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel 2015 Healthcare Conference on November 17, 2015, at 1:30 p.m. Eastern Time.
THLD: 0.47 (-0.02)
Preclinical Studies Find That Tarloxotinib May Overcome Resistance to EGFR Tyrosine Kinase Inhibitors
Marketwired - Fri Nov 06, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preclinical data demonstrating that tarloxotinib bromide*, or tarloxotinib, may overcome resistance to first- and second- and third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The data will be reported today in two scientific posters (Abstracts A66 and A67) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting being held November 5-9, 2015, Boston. Tarloxotinib is Threshold's proprietary hypoxia-activated prodrug of an irreversible EGFR TKI exclusively licensed from the University of Auckland, New Zealand.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Announces Preclinical Data on Combination of Evofosfamide With Immune Checkpoint Inhibitors to Be Presented at the SITC 2015 Meeting
Marketwired - Tue Nov 03, 7:10AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that preclinical data on the combination of evofosfamide with immune checkpoint inhibitors will be presented in a scientific poster at the Society for Immunotherapy of Cancer (SITC) annual meeting in Maryland, November 4-8, 2015. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully-enrolled Phase 3 clinical trials for which Threshold expects to announce top-line data around the end of 2015.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Reports Third Quarter 2015 Financial and Operational Results
Marketwired - Mon Nov 02, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the third quarter 2015. Revenue for the third quarter ended September 30, 2015 was $3.7 million. The operating loss for the third quarter ended September 30, 2015 was $6.8 million. The net loss for the third quarter ended September 30, 2015 was $6.4 million, which included the operating loss of $6.8 million and non-cash income of $0.3 million related to the changes in fair value of the Company's outstanding warrants and was classified as other income (expense). As of September 30, 2015, Threshold had $56.4 million in cash, cash equivalents and marketable securities, with no debt outstanding.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Announces Preclinical Data Presentations on Tarloxotinib at the 2015 AACR-NCI-EORTC Meeting
Marketwired - Tue Oct 27, 6:00AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it will present preclinical data on tarloxotinib bromide*, or "tarloxotinib", in two scientific posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held November 5-9, 2015, in Boston. Tarloxotinib is Threshold's proprietary hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor exclusively licensed from the University of Auckland, New Zealand. The data highlight preclinical rationale in support of two ongoing Phase 2 proof-of-concept trials of tarloxotinib in non-small cell lung cancer and in squamous cell carcinomas of the head and neck or skin.
THLD: 0.47 (-0.02)
Commit To Buy Threshold Pharmaceuticals At $2.50, Earn 48.7% Annualized Using Options
StockOptionsChannel.com - Tue Oct 20, 10:32AM CDT
Investors eyeing a purchase of Threshold Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.91/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals wins two patents for Tarloxotinib Bromide in the US
M2 - Tue Oct 13, 6:37AM CDT
Biotechnology company Threshold Pharmaceuticals (NASDAQ:THLD) reported on Tuesday that it has been granted two patents protecting tarloxotinib bromide, or "tarloxotinib" by US Patent and Trademark Office (USPTO).
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Receives Two U.S. Patents for Tarloxotinib Bromide
Marketwired - Tue Oct 13, 6:00AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first two U.S. patents protecting tarloxotinib bromide*, or "tarloxotinib," the Company's proprietary hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor exclusively licensed from the University of Auckland, New Zealand. The first patent, U.S. Patent No. 9,073,916, generically covers a structural class of EGFR tyrosine kinase inhibitor prodrugs, including tarloxotinib, and pharmaceutical compositions containing this structural class of prodrugs. The second patent, U.S. Patent No. 9,101,632, specifically covers the compound tarloxotinib and pharmaceutical compositions containing it.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Highlights Multiple Presentations at the 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 7:30AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced multiple presentations on clinical trials on its hypoxia-activated prodrugs, evofosfamide and tarloxotinib at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 through 7, 2016 in Chicago, Ill.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 7:30AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Jefferies 2016 Healthcare Conference at the Grand Hyatt in New York City on June 7, 2016 at 3:30 p.m. Eastern Time.
THLD: 0.47 (-0.02)
What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech
PR Newswire - Wed May 18, 7:38AM CDT
The Biotech industry continues to face a wave of challenges, but it does not mean that there are no opportunities ahead. Today, ActiveWallSt.com has on its list these four equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Seattle Genetics Inc. (NASDAQ: SGEN), Chiasma Inc. (NASDAQ: CHMA), and Ophthotech Corp. (NASDAQ: OPHT). Sign up now to receive our free insights and trading alerts at:
SGEN: 40.38 (-0.63), OPHT: 56.33 (+0.17), THLD: 0.47 (-0.02), CHMA: 2.91 (-0.23)
Threshold Pharmaceuticals posts 1Q loss
Automated Insights - Thu May 05, 5:28PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Threshold Pharmaceuticals Inc. (THLD) on Thursday reported a loss of $7.9 million in its first quarter.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Appoints Stew Kroll as Chief Operating Officer
GlobeNewswire - Mon Mar 21, 7:00AM CDT
Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, announced the appointment of Stewart M. Kroll as Chief Operating Officer. Mr. Kroll will serve as the Company's principal operating officer, will continue to report to Barry Selick, CEO, and will be responsible for the design and execution of Threshold's clinical development programs.
THLD: 0.47 (-0.02)
Top Penny Stocks to Watch, Friday 3/11/2016
ACCESSWIRE - Fri Mar 11, 9:56AM CST
CORAL GABLES, FL / ACCESSWIRE / March 11, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. THLD, VCEL, KTOS, and PPCH have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, NASDAQ, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals posts 4Q profit
Automated Insights - Thu Mar 10, 6:29PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Threshold Pharmaceuticals Inc. (THLD) on Thursday reported fourth-quarter net income of $69.7 million, after reporting a loss in the same period a year earlier.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Thu Mar 10, 3:05PM CST
-- Rights to Evofosfamide and Relevant Merck KGaA, Darmstadt, Germany Technology Returned to Threshold; Merck KGaA, Darmstadt, Germany Retains Certain Royalty and Milestone Payments Dependent Upon Successful Development and Commercialization of Evofosfamide --
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Announces Workforce Reduction
Marketwired - Fri Dec 18, 3:05PM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it has initiated a significant reduction in its workforce in order to focus the company's financial resources in the near term on two ongoing Phase 2 proof-of-concept clinical trials of tarloxotinib bromide* ("tarloxotinib"
, the company's novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) licensed from the University of Auckland, New Zealand. THLD: 0.47 (-0.02)
The Only Bit of "Good News" From 2015
ACCESSWIRE - Mon Dec 14, 10:08AM CST
WINDSOR, ON / ACCESSWIRE / December 14, 2015 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device and general healthcare stocks making news and subsequent market moves, would like to mention a few highlights from 2014/ 2015 in the crazy world of biotech investing. IMMU: 3.05 (-0.08), ADRO: 11.99 (-0.43), MRK: 56.81 (-0.37), AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48), THLD: 0.47 (-0.02), BMY: 72.65 (-0.08)
Beyond Chemotherapy: 4 Unique Ways Drug Developers Are Fighting Back Against Cancer
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 22, 8:12AM CST
Image source: National Cancer Institute. Cancer drugs are a fast-growing business for drug developers. According to figures from IMS Health , global oncology sales topped $100 billion in 2014, and this figure could grow by as much as 47% by 2018....
OMED: 11.81 (-0.04), PFE: 35.29 (-0.02), MRK: 56.81 (-0.37), THLD: 0.47 (-0.02), BMY: 72.65 (-0.08)
Threshold Pharmaceuticals Enters Into Definitive Co-Promotion Agreement for Evofosfamide With Merck KGaA, Darmstadt, Germany
Marketwired - Wed Nov 18, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck KGaA, Darmstadt, Germany pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide (previously known as TH-302) in the U.S. subject to Food and Drug Administration (FDA) approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2015 Healthcare Conference
Marketwired - Wed Nov 11, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel 2015 Healthcare Conference on November 17, 2015, at 1:30 p.m. Eastern Time.
THLD: 0.47 (-0.02)
Preclinical Studies Find That Tarloxotinib May Overcome Resistance to EGFR Tyrosine Kinase Inhibitors
Marketwired - Fri Nov 06, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preclinical data demonstrating that tarloxotinib bromide*, or tarloxotinib, may overcome resistance to first- and second- and third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The data will be reported today in two scientific posters (Abstracts A66 and A67) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting being held November 5-9, 2015, Boston. Tarloxotinib is Threshold's proprietary hypoxia-activated prodrug of an irreversible EGFR TKI exclusively licensed from the University of Auckland, New Zealand.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Announces Preclinical Data on Combination of Evofosfamide With Immune Checkpoint Inhibitors to Be Presented at the SITC 2015 Meeting
Marketwired - Tue Nov 03, 7:10AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that preclinical data on the combination of evofosfamide with immune checkpoint inhibitors will be presented in a scientific poster at the Society for Immunotherapy of Cancer (SITC) annual meeting in Maryland, November 4-8, 2015. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully-enrolled Phase 3 clinical trials for which Threshold expects to announce top-line data around the end of 2015.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Reports Third Quarter 2015 Financial and Operational Results
Marketwired - Mon Nov 02, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the third quarter 2015. Revenue for the third quarter ended September 30, 2015 was $3.7 million. The operating loss for the third quarter ended September 30, 2015 was $6.8 million. The net loss for the third quarter ended September 30, 2015 was $6.4 million, which included the operating loss of $6.8 million and non-cash income of $0.3 million related to the changes in fair value of the Company's outstanding warrants and was classified as other income (expense). As of September 30, 2015, Threshold had $56.4 million in cash, cash equivalents and marketable securities, with no debt outstanding.
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Announces Preclinical Data Presentations on Tarloxotinib at the 2015 AACR-NCI-EORTC Meeting
Marketwired - Tue Oct 27, 6:00AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it will present preclinical data on tarloxotinib bromide*, or "tarloxotinib", in two scientific posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held November 5-9, 2015, in Boston. Tarloxotinib is Threshold's proprietary hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor exclusively licensed from the University of Auckland, New Zealand. The data highlight preclinical rationale in support of two ongoing Phase 2 proof-of-concept trials of tarloxotinib in non-small cell lung cancer and in squamous cell carcinomas of the head and neck or skin.
THLD: 0.47 (-0.02)
Commit To Buy Threshold Pharmaceuticals At $2.50, Earn 48.7% Annualized Using Options
StockOptionsChannel.com - Tue Oct 20, 10:32AM CDT
Investors eyeing a purchase of Threshold Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.91/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals wins two patents for Tarloxotinib Bromide in the US
M2 - Tue Oct 13, 6:37AM CDT
Biotechnology company Threshold Pharmaceuticals (NASDAQ:THLD) reported on Tuesday that it has been granted two patents protecting tarloxotinib bromide, or "tarloxotinib" by US Patent and Trademark Office (USPTO).
THLD: 0.47 (-0.02)
Threshold Pharmaceuticals Receives Two U.S. Patents for Tarloxotinib Bromide
Marketwired - Tue Oct 13, 6:00AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first two U.S. patents protecting tarloxotinib bromide*, or "tarloxotinib," the Company's proprietary hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor exclusively licensed from the University of Auckland, New Zealand. The first patent, U.S. Patent No. 9,073,916, generically covers a structural class of EGFR tyrosine kinase inhibitor prodrugs, including tarloxotinib, and pharmaceutical compositions containing this structural class of prodrugs. The second patent, U.S. Patent No. 9,101,632, specifically covers the compound tarloxotinib and pharmaceutical compositions containing it.
THLD: 0.47 (-0.02)
